Expertise in
2
conditions

Marcelo H. Losso

Hospital General De Agudos Dr. José María Ramos Mejía, 
Ramos Mejia, B, AR 
Expertise in
2
conditions
Hospital General De Agudos Dr. José María Ramos Mejía, 
Ramos Mejia, B, AR 

Overview

Marcelo Losso practices practicing medicine in Ramos Mejia, Argentina.

Mr. Losso is highly rated in 2 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Flu, and COVID-19.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Hospital General De Agudos Dr. José María Ramos Mejía, Ramos Mejia, B, Argentina
Other Locations
B, Argentina
Buenos Aires, C, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
Enrollment Status: Terminated
Publish Date: August 13, 2026
Intervention Type: Biological, Other
Study Drug: Hyperimmune Immunoglobulin to SARS-CoV-2 (hIVIG)
Study Phase: Phase 3
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
Enrollment Status: Unknown
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drugs: NRTIs, Dolutegravir, Darunavir, Ritonavir
Study Phase: Phase 4
An International Observational Study of Outpatients With SARS-CoV-2 Infection
An International Observational Study of Outpatients With SARS-CoV-2 Infection
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Other
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Hyperimmune immunoglobulin to SARS-CoV-2, Remdesivir
Study Phase: Phase 3
COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL
COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL
Enrollment Status: Completed
Publish Date: March 18, 2022
Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria
Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria
Enrollment Status: Completed
Publish Date: September 30, 2020
Intervention Type: Other
Study Phase: Not Applicable
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 8 Less Clinical Trials

75 Total Publications

Barriers to timely HIV diagnosis in the rapid testing era
Barriers to timely HIV diagnosis in the rapid testing era
Journal: Medicina
Published: August 16, 2026

Frequently Asked Questions about Marcelo H. Losso

Is Marcelo H. Losso a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Marcelo H. Losso is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marcelo H. Losso participate in research or clinical trials?

Yes. Marcelo H. Losso has published 75 articles and abstracts on conditions like HIV/AIDS. You can view a list of Marcelo H. Losso's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Losso's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile